The Walter Reed Army Institute of Research and its U.S. Military HIV Research Program (MHRP) publish findings with the Statistical Center for HIV/AIDS Research and
Prevention (SCHARP) at the Fred Hutchinson Cancer Research Center and the University of Washington.
September 10, 2012 (SILVER SPRING, Md.) – Scientists used genetic sequencing to discover new evidence that the first vaccine shown to prevent HIV infection in
people also affected the viruses in those who did become infected. Viruses with two genetic "footprints" were associated with greater vaccine efficacy.
The results were published today in the online edition of the journal Nature.
"This is the first time that we have seen pressure on the virus at the genetic level due to an effective HIV vaccine,"
said Morgane Rolland, Ph.D., a scientist at the U.S. Military HIV Research Program and lead author of the study.
The analysis revealed evidence of a vaccine-induced immune response on two sites of Env-V2 region located on HIV's outer coat.
For viruses carrying these two particular signatures, the vaccine efficacy increased to 80 percent.
"These findings reinforce both the RV144 result and the previous study showing that antibodies directed at the V1V2 region reduce the risk of infection.
Taken together the work suggests that the Env-V2 region could be a critical target for future HIV vaccines," noted Col. Jerome Kim, senior author on the study.
"Genetic sequencing is an important and independent assessment of the immune responses induced by the vaccine," said Paul Edlefsen, Ph.D., a biostatistitian at the
Statistical Center for HIV/AIDS Research and Prevention (SCHARP) who co-led the study. Researchers examined HIV genome sequences from 110 volunteers who participated in the Thai HIV vaccine trial,
RV144, and who subsequently became infected with HIV. Results indicated that the HIV viruses infecting trial participants were different in persons who received vaccine compared to those who
Researchers focused their analysis on the V2 portion of the HIV virus after a study published earlier in 2012 found that antibodies specific to the V1V2 region of the HIV genome
correlated with lower risk of infection. This new genetic sequencing study showed that the viruses that broke through or escaped from these immune responses have genetic differences in the same V2 region,
indicating that the vaccine exerted pressure in this region.
HIV viruses that escape from antibodies and manage to infect a person have genetic footprints, or mutations, that can prevent them from being recognized by the immune system.
These changes can be seen in the genetic sequence of the virus. The research team sequenced more than a thousand full-length viruses to look very carefully at which changes corresponded to "escape"
"This study underscores the realistic optimism you see in the HIV vaccine research field today. We are making substantive progress in understanding what it will take to develop
a more effective HIV vaccine which will ultimately help us end this pandemic." said Col. Nelson Michael, director of MHRP.
The study team included researchers with the U.S. Army's Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research, The Statistical Center for HIV/AIDS
Research and Prevention (SCHARP) at the Fred Hutchinson Cancer Research Center and the University of Washington. The project was supported by the National Institute of Allergy and Infectious
Diseases (NIAID), part of the National Institutes of Health, and a cooperative agreement between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department
of Defense (DoD).
# # #
S. Rerks-Ngarm et al., Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. NEJM DOI: 10.1056/NEJMoa0908492 (2009).
BF Haynes et al. Immune correlates analysis of the ALVAC-AIDSVAX HIV-1 vaccine efficacy trial. NEJM DOI: 10.1056/NEJMoa1113425 (2012).
For additional information and photos, please visit www.hivresearch.org
Results from RV144, an Army-led clinical trial involving more than 16,000 adult volunteers in Thailand, were published in the New England Journal of
Medicine in 2009. The results showed that the prime-boost combination of ALVAC® HIV and AIDSVAX® B/E was safe and lowered the rate of HIV infection by an
estimated 31.2% compared with placebo (p=0.04).
These data provided the first evidence in humans that a safe and effective preventive HIV vaccine is possible.
Results from extensive RV144 laboratory studies were published On April 5, 2012 in the New England Journal of Medicine. These studies showed that antibodies (IgG) specific to a particular region
(called V1V2) of the HIV outer coat (envelope protein) correlated with lower infection rates among those who were vaccinated.
The US Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research conducts research to develop an effective HIV vaccine and
integrates prevention, treatment, diagnosis and monitoring as part of a global effort to protect troops and reduce the impact of HIV worldwide. MHRP has six
clinical research sites in the U.S., Africa and Asia. The program successfully collaborates on HIV prevention care and treatment services,
funded by the President's Emergency Plan for AIDS Relief (PEPFAR), with African militaries and in the communities where it conducts research. For more information, visit